U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07041437) titled 'Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer' on June 19.
Brief Summary: Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Advanced Breast Cancer
Intervention:
DRUG: SHR-A2102
ADC
DRUG: Adebrelimab
PD-L1 inhibitor
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fudan University
Information provided by (Responsible Party): Hongxia Wang, Fudan University
Published by HT Digital Content Services with permission from Health Daily Digest....